The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG).
Cynthia Wetmore
No relevant relationships to disclose
Alberto Broniscer
No relevant relationships to disclose
David Turner
No relevant relationships to disclose
Karen D. Wright
No relevant relationships to disclose
Atmaram Pai-Panandiker
No relevant relationships to disclose
Larry E. Kun
No relevant relationships to disclose
Abhijit Ramachandran
Employment or Leadership Position - Arog
Stock Ownership - Arog
Arzu Onar-Thomas
No relevant relationships to disclose
Jie Huang
No relevant relationships to disclose
Amar J. Gajjar
No relevant relationships to disclose
Suzanne Baker
No relevant relationships to disclose
Clinton F. Stewart
No relevant relationships to disclose